Kreshnik Zejnullahu

9.5k total citations · 2 hit papers
17 papers, 5.5k citations indexed

About

Kreshnik Zejnullahu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Kreshnik Zejnullahu has authored 17 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Kreshnik Zejnullahu's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Kreshnik Zejnullahu is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Kreshnik Zejnullahu collaborates with scholars based in United States, Japan and Spain. Kreshnik Zejnullahu's co-authors include Pasi A. Jänne, Jeffrey A. Engelman, Bruce E. Johnson, James G. Christensen, Andrew M. Rogers, Xiao‐Jun Zhao, Lewis C. Cantley, Charles Lee, Neal I. Lindeman and Federico Cappuzzo and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Kreshnik Zejnullahu

15 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

2007 598 citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kreshnik Zejnullahu United States	9	3.2k	3.1k	3.1k	956	550	17	5.5k
Youngchul Song United States	13	2.7k 0.8×	3.0k 1.0×	3.0k 1.0×	908 0.9×	577 1.0×	18	5.5k
Andrew M. Rogers United States	12	2.7k 0.8×	2.6k 0.8×	2.4k 0.8×	994 1.0×	568 1.0×	21	4.7k
Todd M. Bauer United States	50	4.2k 1.3×	5.4k 1.7×	2.9k 0.9×	1.5k 1.6×	697 1.3×	264	8.6k
Courtney Hyland United States	2	2.1k 0.7×	2.0k 0.6×	1.9k 0.6×	683 0.7×	398 0.7×	4	3.6k
Takayuki Kosaka Japan	32	6.5k 2.0×	5.6k 1.8×	3.8k 1.2×	1.8k 1.9×	726 1.3×	93	9.3k
Helena A. Yu United States	41	6.6k 2.1×	5.5k 1.7×	3.1k 1.0×	2.0k 2.1×	591 1.1×	195	8.4k
Ryohei Katayama Japan	31	3.2k 1.0×	3.2k 1.0×	2.9k 0.9×	1.0k 1.1×	730 1.3×	86	5.4k
J. Guillermo Paez United States	8	5.4k 1.7×	4.7k 1.5×	3.6k 1.2×	2.0k 2.1×	537 1.0×	9	8.6k
Daniel B. Costa United States	49	8.4k 2.6×	6.8k 2.2×	3.6k 1.1×	2.2k 2.3×	712 1.3×	169	10.4k
Mark S. Huberman United States	30	3.3k 1.0×	3.0k 1.0×	1.2k 0.4×	778 0.8×	353 0.6×	80	4.5k

Countries citing papers authored by Kreshnik Zejnullahu

Since Specialization

Citations

This map shows the geographic impact of Kreshnik Zejnullahu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kreshnik Zejnullahu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kreshnik Zejnullahu more than expected).

Fields of papers citing papers by Kreshnik Zejnullahu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kreshnik Zejnullahu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kreshnik Zejnullahu. The network helps show where Kreshnik Zejnullahu may publish in the future.

Co-authorship network of co-authors of Kreshnik Zejnullahu

This figure shows the co-authorship network connecting the top 25 collaborators of Kreshnik Zejnullahu. A scholar is included among the top collaborators of Kreshnik Zejnullahu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kreshnik Zejnullahu. Kreshnik Zejnullahu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Ayoola, A. A. & Kreshnik Zejnullahu. (2025). Empyema Necessitans. New England Journal of Medicine. 393(22). e38–e38.

Zejnullahu, Kreshnik, et al.. (2016). Diffuse Alveolar Hemorrhage: Blood, Sweat and Tears. Journal of General Internal Medicine. 31(7). 812–813. 1 indexed citations

Zejnullahu, Kreshnik, et al.. (2016). Approaches to minimize castration in the treatment of advanced prostate cancer. Urologic Oncology Seminars and Original Investigations. 34(8). 368–374. 5 indexed citations

Unni, Arun M., William W. Lockwood, Kreshnik Zejnullahu, Shih-Queen Lee-Lin, & Harold Varmus. (2015). Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife. 4. e06907–e06907. 125 indexed citations

Lockwood, William W., Kreshnik Zejnullahu, James E. Bradner, & Harold Varmus. (2012). Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proceedings of the National Academy of Sciences. 109(47). 19408–19413. 277 indexed citations

Cortot, Alexis B., Claire E. Repellin, Takeshi Shimamura, et al.. (2012). Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research. 73(2). 834–843. 163 indexed citations

Yonesaka, Kimio, Isamu Okamoto, Taroh Satoh, et al.. (2012). Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab. Cancer Research. 72(8_Supplement). 4833–4833. 4 indexed citations

Yonesaka, Kimio, Kreshnik Zejnullahu, Isamu Okamoto, et al.. (2011). OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. European Journal of Cancer. 47. S10–S10. 80 indexed citations

Zejnullahu, Kreshnik, et al.. (2011). Abstract 251: Kinome-wide RNAi screen identification of synthetic lethal interactions in BRAF-mutant melanoma. Cancer Research. 71(8_Supplement). 251–251. 1 indexed citations

10.

Ercan, Dalia, Kreshnik Zejnullahu, Kimio Yonesaka, et al.. (2010). Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 29(16). 2346–2356. 181 indexed citations

11.

Yonesaka, Kimio, Kreshnik Zejnullahu, Neal I. Lindeman, et al.. (2008). Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research. 14(21). 6963–6973. 96 indexed citations

12.

Yonesaka, Kimio, et al.. (2008). Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab. Cancer Research. 68(9_Supplement). 4958–4958. 1 indexed citations

13.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 316(5827). 1039–1043. 3570 indexed citations breakdown →

14.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Eugene Lifshits, et al.. (2007). PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib. Cancer Research. 67(24). 11924–11932. 598 indexed citations breakdown →

15.

Park, Joon Oh, Feng Zhao, Kreshnik Zejnullahu, et al.. (2007). C1-07: IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.. Journal of Thoracic Oncology. 2(8). S361–S361. 1 indexed citations

16.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors. Journal of Thoracic Oncology. 2(8). S396–S396. 1 indexed citations

17.

Engelman, J. A., Toru Mukohara, Kreshnik Zejnullahu, et al.. (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation. 116(10). 2695–2706. 374 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact